CDX2 and cancer: SOS1, RASA1, and NF1 mutations were also significantly more often observed in CDX2-suppressed cancers (10.8%, 9.2% and 13.8%, respectively) than in non CDX2-suppressed cancers (1.8%, 1.8%, and 0.9%, Fisher’s exact test p = 0.003, 0.009, and 0.0001, respectively, Figure 2).